A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT ID: NCT05416749

Last Updated: 2024-11-20

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 216 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-05
• Study Completion Date: 2026-03-31

Brief Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV) infusion.

Conditions

Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

8MW2311

Group Type: EXPERIMENTAL

8MW2311

Intervention Type: DRUG

All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.

Interventions

8MW2311

All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, aged≥18 years old;

2. Histologically or cytologically confirmed locally advanced or metastatic solid tumor;

3. Subjects must have measurable disease according to RECIST (version 1.1)；

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;

5. Life expectancy >3 months;

6. Adequate organ performance based on laboratory blood tests;

7. Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy；

8. Ability to understand and the willingness to sign a written informed consent document；

Exclusion Criteria

1. History of other malignancy within 3 years before the first dose of study drug.

2. History of IL-2 or IL-2 analogues anticancer therapy.

3. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug, or any other anticancer therapy within 14 days prior to the first dose of study drug.

4. Major surgery within 28 days prior to first dose of study drug.

5. Any live vaccines within 28 days before first dose of study drug or during the study.

6. Systemic glucocorticoids or other immunosuppressants received within 14 days before first dose of study drug.

7. Toxicity related to preexisting treatment ≥Grade 2.

8. Central nervous system metastasis and/or cancerous meningitis.

9. Inadequately controlled body cavity effusions.

10. Interstitial pneumonia or interstitial lung disease, other pneumonia history or active pneumonia that may interfere with the judgement of immune-related pulmonary toxicity.

11. Active autoimmune disease, or autoimmune diseases history with recurrence possibility.

12. Clinically significant cardiac or cerebrovascular disease.

13. Use of any investigational drug within 28 days prior to the first dose of study drug.

14. Known sensitivity to any of the ingredients of the study drug.

15. Known active hepatitis B or C infection, or other serious infection.

16. History of drug abuse or drug addiction.

17. Pregnancy or lactation.

18. Other disease or condition which may put the subject at significant risk.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jian Zhang

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

The first affiliated hospital of bengbu medicial college

Bengbu, Anhui, China

Hunan cancer hospital

Changsha, Hunan, China

Jian Zhang

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

8MW2311-2022-CP101

Identifier Type: -

Identifier Source: org_study_id